← Leaderboards
Elizabeth Frances Redente
National Jewish Health
$4,940,326
Attributed
$5,693,138
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,693,138 · 5
VA$0 · 1
By mechanism
R01$5,512,412 · 3
F32$150,726 · 1
R13$30,000 · 1
IK2$0 · 1
Top collaborators
- Peter M Henson2 shared
- David Albert Schwartz1 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Gary L. Johnson$39,128,449
- Dennis R Voelker$17,845,148
- Robert Carl Murphy$18,062,548
- Peter M Henson$23,575,855
- Christina Carroll Leslie$11,280,080
Others in their field
Top investigators on “Fibrosis”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Peter Scott Heeger · Case Western Reserve University$58,406,959
- John F Engelhardt · University Of Iowa$51,265,353
- David Albert Schwartz · Va Eastern Colorado Health Care System$41,842,857
- Richard C Boucher · University Of North Carolina Chapel Hill$33,165,173
- Bruce A. Stanton · Dartmouth College$32,494,343
Research focus
FibrosisLungResolutionResponsePulmonary FibrosisApoptosisCollagenInterstitial Lung DiseasesTissuesPathway InteractionsEffective TherapyTherapeutic InterventionLung DiseasesDiagnosisMolecularPlayInflammatoryBleomycinFibroblastsIn VivoMediatingCicatrixCellsInsight
Grant awards (18)
Activation of matrix metalloproteinase-9 is essential to overcome failed fibrosis resolution$678,756
R01 · FY2025 · HL · contact PI
Activation of matrix metalloproteinase-9 is essential to overcome failed fibrosis resolution$678,756
R01 · FY2024 · HL · contact PI
Aspen Lung Conference Pulmonary Fibrosis - focusing on the future$30,000
R13 · FY2024 · HL · contact PI
Roles for interstitial and airspace macrophages in resolution of pulmonary inflammation$729,844
R01 · FY2023 · HL
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution$547,555
R01 · FY2023 · HL · contact PI
Roles for interstitial and airspace macrophages in resolution of pulmonary inflammation$745,780
R01 · FY2022 · HL
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution$541,587
R01 · FY2022 · HL · contact PI
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution$535,793
R01 · FY2021 · HL · contact PI
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution$530,168
R01 · FY2020 · HL · contact PI
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution$524,173
R01 · FY2019 · HL · contact PI
Mechanisms of TNF-alpha Mediated Resolution of Pulmonary Fibrosis$0
IK2 · FY2019 · VA · contact PI
Mechanisms of TNF-alpha Mediated Resolution of Pulmonary Fibrosis$0
IK2 · FY2018 · VA · contact PI
Mechanisms of TNF-alpha Mediated Resolution of Pulmonary Fibrosis$0
IK2 · FY2017 · VA · contact PI
Mechanisms of TNF-alpha Mediated Resolution of Pulmonary Fibrosis$0
IK2 · FY2016 · VA · contact PI
Mechanisms of TNF-alpha Mediated Resolution of Pulmonary Fibrosis$0
IK2 · FY2015 · VA · contact PI
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis$53,042
F32 · FY2011 · HL · contact PI
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis$50,474
F32 · FY2010 · HL · contact PI
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis$47,210
F32 · FY2009 · HL · contact PI